CD274 and cancer: Our in vitro and ex vivo data using healthy and cancer patient derived canine PBMCs underscore cross-functionality of atezolizumab, an approved PD-L1 blocker, between humans and dogs and provide a rationale for clinical testing of atezolizumab in veterinary oncology.